Life science company ValiRx plc (AIM: VAL) on Monday announced a co-marketing agreement between its subsidiary Inaphaea BioLabs Limited and US-based Spanios LLC.
This partnership will combine Inaphaea's high-throughput drug screening services, which use Patient Derived Cells (PDC), with Spanios' proprietary Patient Derived Tumoroids (PDT).
Both companies will share service royalties from contracts introduced by either party.
The agreement, initially set for 12 months, allows for co-marketing of their respective services and may be extended.
ValiRx continues to focus on accelerating early-stage cancer therapeutics and women's health by advancing novel drug candidates from pre-clinical development to investor-ready assets.
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director